Investigation of the stability and cellular uptake of self-associated monoclonal antibody (MAb) nanoparticles by non-small lung cancer cells

Molecular Pharmaceutics

Volumn 10, Issue 9, 2013, Pages 3275-3284

  Srinivasan, Asha R ^a   Lakshmikuttyamma, Ashakumary ^a   Shoyele, Sunday A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

endocytosis; Monoclonal antibodies; nanoparticles; non small cell lung cancer; oncoproteins

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY; NANOPARTICLE;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG STABILITY; DRUG UPTAKE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INTERNALIZATION; LUNG NON SMALL CELL CANCER; PINOCYTOSIS; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; ENDOCYTOSIS; HUMANS; NANOPARTICLES;

EID: 84883567256     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3005935     Document Type: Article

References (39)

1. Cheng, B.-X.; Erlanger, C. B. Intracellular delivery of monoclonal antibodies Immunol. Lett. 2002, 84, 63-67
2. Guo, K.; Li, J.; Tang, J. P.; Tan, C. P. B.; Wang, H.; Qi, Z. Monoclonal antibodies target intracellular PRL phosphatase to inhibit cancer metastases in mice Cancer Biol. Ther. 2008, 7, 750-757
3. Guo, K.; Li, J.; Tang, J. P.; Tan, C. P. B.; Hong, C. W.; Al Aidaross, A. Q.; Varghase, L.; Huang, C.; Zeng, Q. Targeting intracellular oncoproteins with antibody therapy or vaccination Sci. Transl. Med. 2011, 3, 99ra85-99ra85
4. Imai, K.; Takaoka, A. Comparing antibody and small molecule therapies for cancer Nat. Rev. Cancer 2006, 6, 714-727
5. Baker, M. Upping the ante on antibodies Nat. Biotechnol. 2005, 23, 1065-1072
6. Guo, K.; Li, J.; Tang, J. P.; Tan, C. P. B.; Wang, H.; Qi, Z. Monoclonal antibodies target intracellular PRL phosphatase to inhibit cancer metastases in mice Cancer Biol. Ther. 2008, 7, 750-757
7. Zeng, Q.; Si, X.; Horstmann, H.; Xu, Y.; Hong, W.; Pallen, C. J. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome J. Biol. Chem. 2000, 275, 21444-21452
8. Rai, P.; Mai, Z.; Chang, S.; Spring, B.; Hassan, T. Targeting intracellular VEGF using nanotechnology for subcellular delivery of bevacizumab improves efficacy of combination therapy against pancreatic cancer Mol. Cancer Ther. 2009, 8 (12 Suppl.) A2
9. Rai, P.; Chang, S. K.; Mai, Z.; Neuman, D.; Hasan, T. Nanotechnology-based combination therapy improves treatment response in cancer models. In Photodynamic Therapy: Back to the future; Proceedings of SPIE Vol. 7380; Kessel, D. H., Ed.; 2009; 73800W-1-II.
10. Gonzalez-Mariscal, L.; Lechuga, S.; Garay, E. Role of tight junctions in cell proliferation and cancer Prog. Histochem. Cytochem. 2007, 42, 1-57
11. Sahay, G.; Kim, J. O.; Kabanov, A. V.; Bronich, T. K. The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents Biomaterials 2010, 31, 923-933
12. Anghileri, L. J.; Dermietzel, R. Cell coat in tumor cells. Effect of trypsin and EDTA: a biochemical and morphological study Oncology 1976, 33, 17-23
13. Anghileri, L. J.; Crone-Escanye, M.-C.; Thouvenot, P. Mechanisms of Gallium-67 accumulation by tumors: role of cell membrane permeability J. Nucl. Med. 1988, 29, 663-668
14. Srinivasan, A.; Shoyele, S. A. Self-Associated Submicron IgG1 Particles for Pulmonary Delivery: Effects of Non-ionic Surfactants on Size, Shape, Stability and Aerosol Performance AAPS PharmSciTech 2012, 14, 200-210
15. Johnson, B.; Ma, P.; West, H.; Kerr, R.; Prager, D.; Sandler, A.; Herbst, R. S.; Stewart, D. J.; Dimery, I.; Heymac, J. V. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. Proc. Am. Soc. Clin. Oncol. 2005, 24 (abstract 7102).
16. Johnson, D. H.; Fehrenbacher, L.; Novotny, W. F.; Herbst, R. S.; Nemunaitis, J. J.; Jablons, D. M.; Langer, C. J.; DeVore, R. F., 3rd.; Gaudreault, J.; Damico, L. A.; Holmgren, E.; Kabbinavar, F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J. Clin. Oncol. 2004, 22, 2184-2191
17. Sandler, A. Bevacizumab in non-small cell lung cancer Clin. Cancer Res. 2007, 13, 4613s-4616s
18. Loges, S.; Schmidt, T.; Carmeliet, P. Mechanisms of resistance to anti-angiogenic therapy and development of third generation anti-angiogenic drug candidates Genes Cancer 2010, 1, 12-25
19. Inoue, S.; Hartman, A.; Branch, C. D.; Bucana, C. D.; Bekele, B. N.; Stephens, L. C.; Chada, S.; Ramash, R. Mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibition effect on lung tumor xenograft Mol. Ther. 2007, 15, 287-294
20. Hamerlik, P.; Lathia, J. D.; Rsmussen, R.; Wu, Q.; Bartkova, J.; Lee, M.; Moudry, P.; Bartek, J.; Fischer, W.; Lucas, J.; Rich, J. N.; Bartek, J. Autocrine VEGF-VEGFR2-Neutropilin-1 signaling promotes glioma stem-like cell viability and tumor growth J. Exp. Med. 2012, 209, 507-520
21. Vlckova, M.; Kalman, F.; Schwarz, M. A. Pharmaceutical application of isoelectric focussing on microchip with imaged UV detection J. Chromatogr., A 2008, 1181, 145-152
22. Wang, Y.; Fei, D.; Vanderlaan, M.; Song, A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in-vitro Angiogenesis 2004, 7, 335-345
23. Gratton, S. E. A.; Ropp, P. A.; Pohlhaus, P. D.; Luft, J. C.; Madden, V. J.; Napier, M. E.; DeSimone, J. M. The effect of particle design on cellular internalization pathways Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 11613-11618
24. Hawe, A.; Kasper, J. C.; Fries, W.; Jiskoot, W. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress Eur. J. Pharm. Sci. 2009, 38, 79-87
25. Doi, E.; Jirgensons, B. Circular dichroism studies on the acid denaturation of gamma-immunoglobulin G and its fragments Biochemistry 1970, 9, 1066-1072
26. Pelton, J. T.; McClean, L. R. Spectroscopic methods for analysis of protein secondary structure Anal. Biochem. 2000, 277, 167-176
27. Gratton, S. E. A.; Napier, M. E.; Ropp, P. A.; Shaomin, T.; DeSimone, J. M. Microfabricated particles for engineered drug therapies: Elucidation into the mechanism of cellular internalization of PRINT particles Pharm. Res. 2008, 25, 2845-2852
28. Sivadasan, K.; Somasundaran, P. Polymer-surfactant interactions and the association behavior of hydrophobically modified hydroxyethylcellulose Colloids Surf. 1990, 49, 229-239
29. Paria, S.; Khilar, K. C. A review on experimental studies of surfactant adsorption at the hydrophilic solid-water interface Adv. Colloid Interface Sci. 2004, 110, 75-97
30. Palla, B.; Shah, D. O. Stabilization of high ionic strength slurries using surfactant mixtures: molecular factors that determine optimal stability J. Colloid Interface Sci. 2002, 256, 143-152
31. Shoyele, S. A.; Slowey, A. Prospects of Formulating Proteins/Peptides as Aerosols for Pulmonary Drug Delivery Int. J. Pharm. 2006, 314, 1-8
32. Dani, B.; Platz, R.; Tzannis, S. T. High concentration formulation feasibility of human immunoglobulin G for subcutaneous administration J. Pharm. Sci. 2007, 96, 1504-1517
33. Doi, E.; Jirgensons, B. Circular dichroism studies on the acid denaturation of gamma-immunoglobulin G and its fragments Biochemistry 1970, 9, 1066-1072
34. Luzio, J. P.; Pryor, P. R.; Bright, N. A. Lysosomes: fusion and function Nat. Rev. Mol. Cell Biol. 2007, 8, 622-632
35. Blanchette, C. D.; Woo, Y. H.; Thomas, C.; Shen, N.; Sulchek, T. A.; Hiddessen, A. L. Decoupling internalization, acidification and phagosomal-endosomal/lysosomal fusion during phagocytosis of InlA coated beads in epithelial cells PLoS One 2009, 4, e6056 10.1371/journal.pone.0006056
36. Cain, C. C.; Sipe, D. M.; Murphy, R. F. Regulation of endocytic pH by the Na+, K+-ATPase in living cells Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 544-548
37. Rosenberg, A. S. Effects of protein aggregates: An immunologic perspective AAPS J. 2006, 8 (3) E501-E507
38. Cleland, J.; Powell, M.; Shire, S. J. The development of stable protein formulations: a close look at protein aggregation, deamidation and oxidation Crit. Rev. Ther. Drug Carrier Syst. 1993, 10, 307-377
39. Hermeling, S.; Schellekens, H.; Crommelin, D. J.; Jiskoot, W. Micelle associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm. Res. 2003, 20, 1903-1907